Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137694

Published: 2020

Journal Articles

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Masumi Ueda, MD, Lan Beppu, Judy Campbell, RN, Mary E. D. Flowers, MD, Jerald P. Radich, MD, Rainer Storb, MD

Blood (2019) 134 (Supplement_1): 702.

https://doi.org/10.1182/blood-2019-126979

Published: 2019

Journal Articles

Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Catherine J. Lee, MD, Soyoung Kim, Heather R. Tecca, Ruta Brazauskas, PhD, Minoo Battiwalla, MD, David K. Buchbinder, MD MSHS, Mary E. D. Flowers, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD, Lori S Muffly, MD

Blood (2018) 132 (Supplement 1): 252.

https://doi.org/10.1182/blood-2018-99-113031

Published: 2018

Journal Articles

Risk Factors for the Development of Cutaneous Melanoma after Allogeneic Hematopoietic Cell Transplantation

Megan Herr, PhD, Rochelle E. Curtis, Margaret A. Tucker, Heather R. Tecca, Eric A. Engels, MD MPH, Elizabeth Cahoon, Minoo Battiwalla, MD, David K. Buchbinder, MD MSHS, Mary E. D. Flowers, MD, Ruta Brazauskas, PhD, Bronwen E. Shaw, MD PhD, Lindsay M. Morton, PhD

Blood (2018) 132 (Supplement 1): 249.

https://doi.org/10.1182/blood-2018-99-116261

Published: 2018

Journal Articles

Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial

Marco Mielcarek, MD, Terrence Furlong, Barry E. Storer, PhD, Margaret L. Green, MD, Paul A. Carpenter, MD, George B McDonald, MD, Mary E. D. Flowers, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Michael Boeckh, MD, Paul J. Martin, MD

Blood (2013) 122 (21): 703.

https://doi.org/10.1182/blood.V122.21.703.703

Published: 2013

Journal Articles

The CIBMTR Chronic GVHD Risk Group Predicts Major Outcomes In An Independent Validation Cohort

Blood (2013) 122 (21): 706.

https://doi.org/10.1182/blood.V122.21.706.706

Published: 2013

Journal Articles

Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients

Monica S Thakar, MD, Mark C. Walters, MD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Mary E. D. Flowers, MD, H. Joachim Deeg, MD, Paul O'Donnell, MD, PhD, Ann E. Woolfrey, MD, Hans-Peter Kiem, MD

Blood (2013) 122 (21): 4561.

https://doi.org/10.1182/blood.V122.21.4561.4561

Published: 2013

Journal Articles

Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis

Alvaro Urbano-Ispizua, MD, Steven Z. Pavletic, MD, Mary E. D. Flowers, MD, Mei-Jie Zhang, PhD, Jeanette Carreras, MPH, Sonali M. Smith, MD, David G. Maloney, MD, PhD, Silvia Montoto, MD, Corey S. Cutler, MD, MPH, FRCPC, Stephen R Spellman, MBS, Mukta Arora, MD, MS, Wael Saber, MD, MS

Blood (2013) 122 (21): 2093.

https://doi.org/10.1182/blood.V122.21.2093.2093

Published: 2013

Journal Articles

Failure-Free Survival After Initial Systemic Treatment Of Chronic GVHD

Yoshihiro Inamoto, MD, PhD, Paul J. Martin, MD, Brenda M. Sandmaier, MD, Sahika Aki, MD, Paul A. Carpenter, MD, Stephanie J. Lee, MD, MPH, Barry E. Storer, PhD, Mary E. D. Flowers, MD

Blood (2013) 122 (21): 2053.

https://doi.org/10.1182/blood.V122.21.2053.2053

Published: 2013

Journal Articles

Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium

Yoshihiro Inamoto, MD, PhD, Barry E. Storer, PhD, Daniel J. Weisdorf, MD, Georgia B. Vogelsang, MD, Joseph Pidala, MD, MS, Xiaoyu Chai, MS, Mary E. D. Flowers, MD, Mukta Arora, MD, MS, Sally Arai, MD, Jeanne Palmer, MD, Corey S. Cutler, MD, Madan Jagasia, MBBS, MS, Steven Z. Pavletic, MD, Stephanie J. Lee, MD, MPH, Paul J. Martin, MD

Blood (2013) 122 (21): 4614.

https://doi.org/10.1182/blood.V122.21.4614.4614

Published: 2013

Journal Articles

Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Andrew R. Rezvani, MD, Barry E. Storer, PhD, Rainer F. Storb, MD, Marco Mielcarek, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Paul J. Martin, MD, Mary E. D. Flowers, MD, George B. McDonald, MD

Blood (2009) 114 (22): 1146.

https://doi.org/10.1182/blood.V114.22.1146.1146

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Risk Factors for the Development of Cutaneous Melanoma after Allogeneic Hematopoietic Cell Transplantation

Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial

The CIBMTR Chronic GVHD Risk Group Predicts Major Outcomes In An Independent Validation Cohort

Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients

Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis

Failure-Free Survival After Initial Systemic Treatment Of Chronic GVHD

Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium

Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only